Faron Board Issues Warrants to IPF Partners
Faron Pharmaceuticals Ltd. (“Faron or Company”) The Board of Directors of Faron Has Resolved on a Warrant Program and an Issuance of 319,944 Warrants to IPF Partners Company announcement, February 28, 2022 - 07:45 PM (EET) / 05:45 PM (GMT) / 12:45 PM (EST) TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announced today, February 28, 2022, that it had entered into a